Pat Olivas
Payments from drug & device makers
Across 36 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$113
- Amgen$104
- Johnson & Johnson$56
- Daiichi Sankyo Inc.$54
- Eisai Inc.$44
- Seagen Inc.$38
- plus $240 from 12 others
What the payments were for
- Food & beverage$650100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 5 | $113 |
| Amgen | 7 | $104 |
| Johnson & Johnson | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $54 |
| Eisai Inc. | 2 | $44 |
| Seagen Inc. | 2 | $38 |
| AstraZeneca | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Karyopharm Therapeutics Inc. | 1 | $25 |
| Novartis | 1 | $23 |
| Medtronic | 1 | $23 |
| Heron Therapeutics, Inc. | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Myovant Sciences Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$650 in reported general payments places this provider in the 60th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $18,856 |
| Letrozole | 89 | $2,224 |
| Exemestane | 31 | $2,185 |
| Tamoxifen Citrate | 51 | $1,293 |
| Hydroxyurea | 25 | $904 |
| Levocetirizine Dihydrochloride | 68 | $522 |
| Omeprazole | 26 | $317 |
| Anastrozole | 33 | $242 |
| Mirtazapine | 26 | $236 |
| Acyclovir | 23 | $233 |
| Dicyclomine Hcl | 16 | $183 |
| Dexamethasone | 13 | $118 |
| Gabapentin | 15 | $106 |
| Prednisone | 25 | $95 |
| Ciprofloxacin Hcl | 12 | $54 |
Paid to pharmacies, not to this prescriber.
Other family in Tift
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.